Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ten23 health | Contract Pharma

What are you searching for?

Sign in

Search by

ten23 health

ten23 health

Company Headquarters

22 Mattenstrasse, Basel, BS, 4058, CH

Driving Directions Phone: View Phone
View website

Company Description

ten23 health, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.  

Request more information from ten23 health

Request more information from ten23 health

Categories from ten23 health

Biosimilars
Contract Development and Manufacturing Organization (CDMO)
Contract Manufacturing
Filling, Cartridge
Filling, Syringe
Filling, Vial
Manufacturing, Aseptic Fill/Finish
Manufacturing, Clinical Trials Supply
Manufacturing, Dose Form, Sterile
Manufacturing, Injectables
Manufacturing, Ophthalmics
Manufacturing, Parenterals, Small Volume
Parenterals, Cartridge Filling
Parenterals, Syringe Filling
Parenterals, Vial Filling

Content From ten23 health

Addressing the Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

Sponsored Content

Addressing the Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

SC administration has been increasing over recent years, especially for frequent and long-term applications to treat chronical diseases.

Released By ten23 health

Related Content

Collaborations & Alliances

Cellares, SNUH Partner on Cell Therapy Manufacturing

The partners will evaluate Cellares’ Cell Shuttle for scalable manufacturing of a gene-modified PNH therapy.

By: Charlie Sternberg

Breaking News

AustinPx KinetiSol Earns FDA AMT Designation

Solvent-free technology expands manufacturing options for poorly soluble oral drug candidates.

By: Charlie Sternberg

Collaborations & Alliances

ExploRNA, Łukasiewicz Research Network Partner on GMP Manufacturing of Next-Gen mRNA Cap Analogs

Łukasiewicz, known for advanced chemical synthesis and production scaling capabilities, will help ExploRNA ramp up its mRNA manufacturing.

By: Patrick Lavery

Breaking News

Lilly Breaks Ground on $6.5B Houston Manufacturing Site

The new Texas facility will produce Lilly’s oral GLP-1 medicine Foundayo and other small-molecule therapies.

By: Charlie Sternberg

Breaking News

WuXi XDC Secures GMP Release for Singapore Manufacturing Site

The designation applies to the site’s BCM3 antibody intermediate and conjugated drug substance dual-function production line, and DP4 facility.

By: Patrick Lavery

Breaking News

Telix to Buy ITM in $1.65B Radiopharma Deal

The acquisition adds isotope production, manufacturing, and late-stage therapeutic assets to Telix’s radiopharmaceutical platform.

By: Charlie Sternberg

Collaborations & Alliances

Bespak and Upperton Partner on Nasal Drug Delivery

The CDMO collaboration will combine Bespak’s nasal device portfolio with Upperton’s formulation, analytical and clinical manufacturing expertise.

By: Charlie Sternberg

Online Exclusives

Addressing Barriers to Access for Today’s Cell and Gene Therapies

Decisions around trial design, regulatory strategy, and manufacturing planning ultimately determine whether a therapy reaches patients.

By: Kristin Brooks

News Releases

Upperton granted MHRA license for Annex 1 aligned sterile manufacturing facility.

Released By Upperton

Breaking News

Upperton Gains MHRA Approval for Nottingham Sterile Manufacturing Site

License variation supports early-phase GMP manufacture at Nottingham facility.

By: Charlie Sternberg

Collaborations & Alliances

Ori Biotech Lands 10-Year, $120M Commercial Cell Therapy Manufacturing Deal

The strategic collaboration was agreed upon with an undisclosed biopharmaceutical company.

By: Patrick Lavery

Online Exclusives

CDMO Capacity: Stainless by Volume, Single-Use by Number

Large stainless-steel projects are rising, but pipeline demand is increasingly moving toward smaller, more flexible manufacturing models.

By: Dan Stanton

Collaborations & Alliances

Axiom, GeneFab Partner to Advance Therapeutic Pipeline

The move expands Axiom’s manufacturing and clinical development capabilities.

By: Patrick Lavery

Collaborations & Alliances

Samsung Biologics Signs $262M Manufacturing Deal With European Pharma Company

The agreement extends manufacturing commitments through 2033 and pushes Samsung Biologics’ cumulative contract value above $21.9 billion.

By: Charlie Sternberg

Breaking News

VVMF Sydney Facility Gets Therapeutic Goods Manufacturing License

The company hopes this will expand access to advanced therapeutics manufacturing not only in Australia, but also across Asia-Pacific.

By: Patrick Lavery